Scleroderma is a rare disease which affects the skin and internal organs. Not all persons diagnosed with it experience the same disease progression. The purpose of this study is to collect sequential blood samples and imaging data over a 5-year period. The study hopes to use this information to better predict who will be likely to undergo disease progression in the future.
FASST (For A Systemic Sclerosis Treatment) is investigating a new drug for treating diffuse cutaneous systemic sclerosis (scleroderma) www.fassttrial.com
To better understand the condition ‘giant cell arteritis’ (including genetics) and it’s impact on peoples lives.
An observational study that collects data to identify disease characteristics. This may predict disease progress and outcome. Includes the collection of blood samples to explore how the disease works on a cellular and molecular level and different imaging approaches to characterise diseases.
National registry of autoimmune vasculitides.
Participation of this study is through a questionnaire. The purpose if to find out what it is like to live with sjogrens, experiences of accessing care when symptoms of sjogrens first began, and the risks associated with this illness. The questionnaire will take about 30 minutes.
Discoid lupus is a form of lupus rash which usually occurs on visible areas of the body. If left untreated, this can lead to permanent scarring. Current treatment with an immunosuppressant antimalarial drug is only effective in about 50% of the patients. This study will test a new drug called etanercept to treat discoid lupus. Etanercept has been approved for other immune conditions like rheumatoid arthritis, psoriasis and psoriatic arthritis. Etanercept will be given through direct injection to the surface of the rash (intradermal) by the doc-tor for 12 weeks. This study also aims to develop new tests to measure skin inflammation by scanning the skin using optical coherence tomography (OCT), thermography and laser doppler imaging (LDI) and taking photographs of the rash. If the findings from these new tests are similar to the ones from taking a sample of skin (biopsy), then the latter (which is an invasive test) can be avoided.
The standard treatment used to reduce the inflammation to the kidney caused by lupus (lupus ne-phritis) is through a combination of high dose corticosteroids and a drug called mycophenolate mo-fetil (MMF). This combination treatment is effective but some patients may experience unwanted side effects from prolonged use of corticosteroids such as weight gain, stretch marks, high blood pressure, thin bones and diabetes. The aim of this study is to investigate whether a different drug called Rituximab in combination with MMF (without corticosteroids) would be as good as the standard treatment. If this is the case, then it would be the first in 60 years that patients with lupus ne-phritis could be spared from burden of long-term corticosteroids.
DEFINITION is an observational study that will examine a new blood marker in people with suspected, established and flaring lupus. The study aims to correlate this blood marker with the signs and symptoms of lupus. The study is expected to open by August 2017 and we will recruit participants through the NHS Rheumatology Clinic at Chapel Allerton Hospital. Funding for this study has been received from AstraZeneca. All major milestones within the study can be followed on Twitter® @studyDEFINITION.